ArticleScientific reports2020
Iodine nanoparticle radiotherapy of human breast cancer growing in the brains of athymic mice.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- Nanoparticle-Based Radiosensitization in Breast Cancer: A Multimodal Approach to Therapy and Immune Regulation.Biotechnology journal · 2026Review
- Overview of Preclinical and Clinical Trials of Nanoparticles for the Treatment of Brain Metastases.Pharmaceutics · 2025Review
- State-of-the-art application of nanoparticles in radiotherapy: a platform for synergistic effects in cancer treatment.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025Review
- Advances in Ultrasmall Inorganic Nanoparticles for Nanomedicine: From Diagnosis to Therapeutics.ACS applied materials & interfaces · 2025Review
- Advancements in Nanoporous Materials for Biomedical Imaging and Diagnostics.Journal of functional biomaterials · 2024Review
- Synthesis and Characterization of Iodinated Chitosan Nanoparticles and Their Effects on Cancer Cells.International journal of biomaterials · 2024Article
- Radiotherapy in Preclinical Models of Brain Metastases: A Review and Recommendations for Future Studies.International journal of biological sciences · 2024Review
- Nanomaterials with dual immunomodulatory functions for synergistic therapy of breast cancer brain metastases.Bioactive materials · 2023Article
- Review
- Recent Advances in Metal-Based NanoEnhancers for Particle Therapy.Nanomaterials (Basel, Switzerland) · 2023Review
- Article
- Review
- Iodine Nanoparticles (NiodxPharmaceutics · 2022Article
- Redox-sensitive iodinated polymersomes carrying histone deacetylase inhibitor as a dual-functional nano-radiosensitizer for enhanced radiotherapy of breast cancer.Drug delivery · 2021Article
- Harnessing nanomedicine for enhanced immunotherapy for breast cancer brain metastases.Drug delivery and translational research · 2021Review
- Harnessing X-Ray Energy-Dependent Attenuation of Bismuth-Based Nanoprobes for Accurate Diagnosis of Liver Fibrosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- Novel Iodine nanoparticles target vascular mimicry in intracerebral triple negative human MDA-MB-231 breast tumors.Scientific reports · 2021Article
- Distributions of intravenous injected iodine nanoparticles in orthotopic u87 human glioma xenografts over time and tumor therapy.Nanomedicine (London, England) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
About 30% of breast cancers metastasize to the brain; those widely disseminated are fatal typically in 3-4 months, even with the best available treatments, including surgery, drugs, and radiotherapy. To address this dire situation, we have developed iodine nanoparticles (INPs) that target brain tumors after intravenous (IV) injection. The iodine then absorbs X-rays during radiotherapy (RT), creating free radicals and local tumor damage, effectively boosting the local RT dose at the tumor. Efficacy was tested using the very aggressive human triple negative breast cancer (TNBC, MDA-MB-231 cells) growing in the brains of athymic nude mice. With a well-tolerated non-toxic IV dose of the INPs (7 g iodine/kg body weight), tumors showed a heavily iodinated rim surrounding the tumor having an average uptake of 2.9% iodine by weight, with uptake peaks at 4.5%. This is calculated to provide a dose enhancement factor of approximately 5.5 (peaks at 8.0), the highest ever reported for any radiation-enhancing agents. With RT alone (15 Gy, single dose), all animals died by 72 days; INP pretreatment resulted in longer-term remissions with 40% of mice surviving 150 days and 30% surviving > 280 days.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.